Compare ARWR & RNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARWR | RNR |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 12.3B |
| IPO Year | 2009 | 1996 |
| Metric | ARWR | RNR |
|---|---|---|
| Price | $85.30 | $330.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 14 |
| Target Price | $83.40 | ★ $322.31 |
| AVG Volume (30 Days) | ★ 1.1M | 240.4K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 0.53% |
| EPS Growth | ★ 99.80 | 59.13 |
| EPS | N/A | ★ 6.57 |
| Revenue | $16,142,321.00 | ★ $12,848,074,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.19 |
| P/E Ratio | ★ N/A | $50.29 |
| Revenue Growth | N/A | ★ 9.86 |
| 52 Week Low | $22.73 | $231.17 |
| 52 Week High | $95.49 | $335.97 |
| Indicator | ARWR | RNR |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 60.30 |
| Support Level | $82.70 | $314.59 |
| Resistance Level | $87.83 | $335.97 |
| Average True Range (ATR) | 2.65 | 5.31 |
| MACD | -0.40 | 0.97 |
| Stochastic Oscillator | 26.08 | 84.70 |
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.